Loading...
Thumbnail Image
Publication

US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty

Guharoy, Roy
Krenzelok, Edward P.
Embargo Expiration Date
Abstract

Recently, the Food and Drug Administration (FDA) issued emergency use authorization (EUA) of convalescent plasma (CP) for the treatment of COVID-19 hospitalized patients based on a non-peer reviewed open label observational study. Issuance of an EUA without a proven randomized control trial (RCT) sets a dangerous precedent since the premature action drives health care providers and patients away from RCTs that are essential for determining the efficacy and safety of CP. More caution should have been taken based on what was learned from the recently rescinded EUA of hydroxychloroquine and chloroquine debacle which was approved initially based on an anecdotal report. The FDA approval process for determining efficacy and safety must be based solely on data from RCTs to sustain public and professional trust for future treatment or vaccine efforts to be successful.

Source

Guharoy R, Krenzelok EP. FDA Emergency Use Authorization: Glass Half Empty? Clin Infect Dis. 2020 Oct 26:ciaa1653. doi: 10.1093/cid/ciaa1653. Epub ahead of print. PMID: 33104216; PMCID: PMC7665427. Link to article on publisher's site

Year of Medical School at Time of Visit
Sponsors
Dates of Travel
DOI
10.1093/cid/ciaa1653
PubMed ID
33104216
Other Identifiers
Notes
Funding and Acknowledgements
Corresponding Author
Related Resources
Related Resources
Repository Citation
Rights
Distribution License